Lanadelumab for COVID-19: real-time analysis

Download Image

Post

c19early.org

Lanadelumab for COVID-19

1 study with 55 patients

Serious outcome risk

Lanadelumab

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Lanadelumab studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−7%

Mortality (1)−7%

RCTs (1)−7%

Late (1)−7%

00.511.5+

← Lanadelumab
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Apr 7 2022	Amgen, NCT04590586	Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
Apr 7 2022	7% higher mortality (p=1), 10% greater improvement (p=0.79), 24% higher hospital discharge (p=0.57), and 9% worse recovery (p=1). RCT 55 hospitalized patients showing no significant difference with lanadelumab treatment.